Unknown

Dataset Information

0

The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians.


ABSTRACT: Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) affect many older men and can have a significant impact on health-related quality of life. BPH is a progressive condition that may lead to complications including acute urinary retention. There exists an unmet need for a safe and effective, office-based, catheter-free therapy for BPH patients. NX-1207 is a promising first-in-class drug currently in phase III trials for the treatment of BPH. This review provides an overview of the NX-1207 trial program and considers its potential application for patients with symptoms related to BPH. NX-1207 is administered as an office-based procedure by transrectal intraprostatic injection under ultrasound guidance. NX-1207 has selective pro-apoptotic properties, which induce focal cell loss in prostate tissue, leading to prostate volume reduction with both short- and long-term symptomatic improvement. In four US clinical trials to date, NX-1207 has shown evidence of symptomatic improvement substantially better than currently approved BPH medications with no significant safety issues. Larger phase III trials are ongoing to confirm further the efficacy, safety, and tolerability for this minimally invasive, anesthetic-free, clinic-based treatment for BPH.

SUBMITTER: Shore N 

PROVIDER: S-EPMC3513892 | biostudies-other | 2011 Nov

REPOSITORIES: biostudies-other

altmetric image

Publications

The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians.

Shore Neal N   Cowan Barrett B  

Therapeutic advances in chronic disease 20111101 6


Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) affect many older men and can have a significant impact on health-related quality of life. BPH is a progressive condition that may lead to complications including acute urinary retention. There exists an unmet need for a safe and effective, office-based, catheter-free therapy for BPH patients. NX-1207 is a promising first-in-class drug currently in phase III trials for the treatment of BPH. This review provides an ov  ...[more]

Similar Datasets

| S-EPMC5780286 | biostudies-literature
| S-EPMC5469601 | biostudies-literature
| S-EPMC7485377 | biostudies-literature
| S-EPMC6833462 | biostudies-literature
| S-EPMC8202600 | biostudies-literature
| S-EPMC9385790 | biostudies-literature
2020-03-18 | GSE124187 | GEO
| S-EPMC3764772 | biostudies-literature
| S-EPMC3936307 | biostudies-literature
| S-EPMC8261417 | biostudies-literature